Insmed Inc (INSM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $120.62 (-2.71%), Market cap $23.39B, 52-week low–high $66.02 ~ $211.41.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and
Financial statements, price targets, institutional (13F) holdings and related news for Insmed Inc are updated in real time on BlackAll Trade.
Insmed Inc trades at $120.62 (-2.71%). Real-time quotes and charts are available on BlackAll Trade.
Insmed Inc has a market cap of about $23.39B.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the trea